HuABC2 is a humanized anti-CD122 IgG antibody with a novel mechanism of action to treat immune-mediated disease and transplant. CD122 is an integral part of both the interleukin-2 (IL-2) and interleukin-15 (IL-15) receptors. HuABC2 which has a high affinity for CD122 is a potent antagonist of both IL-2 and IL-15 activity. In proof-of-concept studies in non-human primates, HuABC2 showed a good safety profile, suppressed renewal of CD8+ memory T cells and NK cells, and demonstrated ability to prolong survival of non-human primates receiving life-sustaining kidney allografts (click here for the abstract of the poster presentation by JN Biosciences' academic collaborators).
ChMBC7, a surrogate of HuABC2, is a rat-mouse chimeric IgG antibody that binds to and blocks the function of mouse CD122. Therapeutic activity of ChMBC7 was demonstrated in mouse disease models of type I diabetes and vitiligo by JN Biosciences' collaborators. Other academic researchers also reported the therapeutic efficacy of an anti-CD122 antibody in the mouse models of celiac disease, type I diabetes and alopecia areata.
HuABC2 is expected to be efficacious for treatment of a variety of immune-mediated diseases in humans, including type I diabetes, vitiligo, alopecia areata, celiac disease, multiple sclerosis, Behcet's disease and organ transplant rejection, in which the involvement of pathogenic CD8+ memory T cells and NK cells are indicated in the onset and/or maintenance of diesease conditions.
For additional information of HuABC2, please contact us by email at info(at)jn-bio.com (convert (at) to @).
